Monday, July 27, 2026

Bridging the Gap Between COVID-19 and Subarachnoid Hemorrhage: A Case Report and Literature Review

 

Bridging the Gap Between COVID-19 and Subarachnoid Hemorrhage: A Case Report and Literature Review

Introduction

The novel coronavirus was reported in December 2019 during a pneumonia epidemic in Wuhan, China. It surged rapidly and the World Health Organization designated it a pandemic on March 11, 2020 [1]. COVID-19 was the term given to the disease induced by the virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Over 559 million confirmed cases and 6.3 million fatalities had been recorded globally as of July 17, 2022 [2]. SARSCoV- 2 infects host cells via Angiotensin Converting Enzyme-2 (ACE-2) receptors, ACE-2 is found on the apical membranes of polarized cells of the testis, cardiovascular epithelium, cardiac myocytes, cardiac fibroblasts, kidney, liver, intestine, brain, and lung epithelial cells, resulting in coronavirus disease (COVID-19)- related pneumonia as well as acute myocardial injury and long-term cardiovascular damage [3,4]. SARS-CoV-2 can potentially infect the nervous system, skeletal muscles, and respiratory tract. Neurologic involvement is increased in patients with severe infections, including acute cerebrovascular disorders, altered consciousness, and skeletal muscle damage [5]. The probable processes behind covid-19 involvement, stroke, and subarachnoid hemorrhage (SAH) are yet unknown. However, according to numerous studies, covid-19 can increase intracranial pressure, increasing the likelihood of an intracranial aneurysm [6]. At the moment, there seems to be minimal information available on the SAH following COVID-19. An overt or covert link between the incidence of spontaneous SAH and COVID-19 has yet to be established. It is crucial to identify parameters for the diagnosis and therapy of patients with COVID-19 infection and SAH. We herein report a case of a non-comorbid young woman infected with SARS-CoV-2 presenting with severe cough and headache and eventually saccular aneurysmal SAH, who recovered with conservative management and a literature review exploring links between SAH and SARS-CoV-2.

Case Report

A 35-year-old Caucasian woman, 178cm, 72kg, presented with nausea, vomiting, dry cough, fever, anosmia, and headache for 5 days. Comorbidities or prior neurological episodes were not reported. The patient was alert and oriented upon admission to the emergency room. The patient denied any family history of brain aneurysms or past medical history of any neurological deficits. The likelihood of infection by the novel coronavirus was raised after reports of cough, fever, and anosmia in the preceding 5 days. As a result, throat swab samples were collected for 2019-CoV RNA RT-PCR, which confirmed SARS-CoV-2 infection. The patient was admitted to ICU to receive hospital care. Within 48 hours of hospital admission, the patient was disoriented and confused and developed acute respiratory failure. After clinical stabilization, a cranial CT scan was performed, and a Fisher score II SAH was visualized (Figures 1 & 2). The patient was placed on ventilation and had suffered a subarachnoid intraventricular hemorrhage. Upon further observation, the dynamic condition did not improve according to neuroimaging, later the patient’s consciousness was suppressed, and her Glasgow Coma Scale (GCS) score was 3. The patient was transferred to Caucasus Medical Center, Evex hospitals, Tbilisi, Georgia, to receive specialist care. Upon admission, the patient was in a comatose state, while her photoreaction and corneal reflexes were sluggish. The patient underwent further testing and a chest CT scan was performed and it demonstrated bilateral glass opacities, suggestive of COVID-19 pneumonia (Figure 3).

A Selective digital cerebral angiography was performed - an aneurysm of a complex configuration, a two-chamber, left posterior cerebral artery aneurysm, with a wide neck saccular aneurysm was detected. A spasm of the basilar artery was also detected as shown in Figures 4 & 5. Based on the angioarchitecture of the aneurysm, and to prevent its re- rupture, endovascular closure was performed via balloon-assisted embolization, and complete occlusion of the aneurysm was achieved. Pharmaco-angioplasty for correction of pronounced vasospasm was performed using Percutaneous Transluminal Angioplasty (PTA) of the basilar artery using Nimodipine I/A infusion (Figures 6 & 7). Based on the angioarchitecture of the aneurysm, and to prevent its rerupture, endovascular closure was performed via balloon-assisted embolization, and complete occlusion of the aneurysm was achieved. Pharmaco-angioplasty for correction of pronounced vasospasm was performed using Percutaneous Transluminal Angioplasty (PTA) of the basilar artery using Nimodipine I/A infusion (Figures 6 & 7). The post-operative period proceeded with positive dynamics, without complications. The patient became more active and the headaches decreased. Neurologically at discharge, the patient experienced clear consciousness, adequate orientation in time and environment, and relatively fewer headaches. The patient was discharged after 24 days, with no neurological disabilities. The patient was advised to rest for 2-3 weeks and begin neurorehabilitation.

biomedres-openaccess-journal-bjstr

Figure 1: Brain CT-scan showing Fisher score II SAH.

biomedres-openaccess-journal-bjstr

Figure 2: Brain CT-scan showing Fisher score II SAH.

biomedres-openaccess-journal-bjstr

Figure 3: A chest CT scan in coronal section reveals ground-glass opacities, indicating lung infection by the new coronavirus

biomedres-openaccess-journal-bjstr

Figure 4: Left Posterior Cerebral Artery Aneurysm.

biomedres-openaccess-journal-bjstr

Figure 5: Coiled Aneurysm.

biomedres-openaccess-journal-bjstr

Figure 6: Basilar artery.

biomedres-openaccess-journal-bjstr

Figure 7: Basilar artery post percutaneous transluminal angioplasty with nimodipine I/A infusion.

Epidemiology

Subarachnoid hemorrhage was the 53rd leading cause of death worldwide in 2019, with 11.2 million cases and 373,000 fatalities and a gross mortality rate of 3.33 percent. Furthermore, 240,000 deaths in patients aged over 60 was noted, compared to 103,000 deaths from patients aged between 40 to 59 [7]. Following the study conducted by Sepide Kashefiolasl et al, 10 dated March 21st, 2022, it discussed the prevalence of COVID-19 and Subarachnoid Hemorrhage concerning the age of the patients. In their study, they retrospectively analyzed some subsamples of patients that independently suffered from COVID-19 and SAH and the other group of patients that shared the homogeneity of both diseases. To make their conclusion more referable they underlined the prepandemic era as well. It was then thereby found that there were 12 out of 56 (21%) patients aged less than 50 with a diagnosis of aSAH whereas in comparison to the pre-covid era there were 19 out of 84 (23%) patients aged less than 50 with a diagnosis of aSAH. Concerning this data there was a conclusion that SAH interlinked with COVID-19 was much more prevalent in patients of young age, to emphasize more on the findings they used multivariable analysis to verify significant factors for a favorable outcome (mRS ≤ 0–2) after aSAH during the COVID pandemic [8]. In another similar study conducted by Qureshi AL et al, 282,718 patients were evaluated to assess the risk of SAH development in patients with COVID-19. It was concluded that 0.3% to 1.2% of the patients develop Sub arachnoid Hemorrhage as a complication of Covid-19 [9]. In a gender-based study of the incidence of SAH in association with Covid, male patients were found to be younger than older female patients. The evident causes of younger age group predominance were cigarette smoking in males and hypercholesterolemia in females [10].

Pathophysiology

SARS-COV-2 is a member of the coronavirus family, namely the Beta coronavirus. Beta coronaviruses are known to frequently infiltrate the central nervous system. This behavior has also been observed in other coronaviruses such as SARS, MERS as well as porcine hemagglutinating encephalomyelitis [11]. SARS-COV-2 infects host cells by entering via angiotensin-converting enzyme-2 receptors (ACE-2). ACE-2 receptors are omnipresent within the human body, particularly overexpressed on intestinal epithelial cells, endothelial and smooth cells of blood vessels, heart, lung, renal tubular epithelial cells [12], and in cerebrovascular endothelium which interacts with the viral “s” protein (homotrimer spike glycoprotein) [13]. A potential risk factor that causes intracranial hemorrhage (ICH) is intracerebral capillaries bursting as a result of direct endothelial toxicity. Additionally, endothelial damage may initiate a series of events involving the coagulation cascade, the complement system, and proinflammatory cytokines. Ultimately, this causes increased permeability, breakdown of cellular tight junctions, and the disruption of the blood-brain barrier leading to ICH. In addition, the renin-angiotensin-aldosterone pathway is disrupted by SARS-Cov-2 suppressing the expression of the ACE- 2 receptor. As a result, the autoregulation of cerebral blood flow is compromised, and the local endothelium accumulates high amounts of angiotensin II. This subsequently results in uncontrolled hypertension, significantly raising the risk of subarachnoid hemorrhage (SAH) and ICH [13].

In microvascular lesions of cerebral hemorrhage, increased D-dimer level enhances fibrinolytic function and plasmin generation, which may result in the hypercoagulable conditions. Elevated D-dimer levels are associated with a hyper-fibrinolytic, pro-inflammatory state in SARS-Cov-2 patients, and these levels have been shown to correlate with the severity of the illness and may raise the risk of intracranial bleeding [14]. Innate and acquired immune responses that are elicited by the virus are the main defense mechanisms that protect the host organisms from the crippling effects of SARS-Cov-2 infections. Identification of pathogen-associated molecular patterns (PAMPs) and induction of antigen-specific adaptive immunity is of prime importance to cause these responses. The body’s response to viral infections is influenced by the secretion of cytokines, chemokines, leukotrienes, proteases, reactive oxygen species, and the rate of viral clearance [15]. Furthermore, SARS-Cov-2 causes systemic inflammation as a result of cytokine down-regulation leading to septic shock [16]. Inflammation associated with SARS-CoV-2 and aneurysmal rupture is both heavily influenced by macrophages. The generation of IL- 1, IL-6, and tumor necrosis factors by macrophages have a role in SARS-CoV-2 infection and cerebral aneurysm rupture [17]. Studies have shown males had higher rates of severe Sars-Cov-2 symptoms necessitating ICU admission and worse ischemic stroke outcomes upon hospital release while females had higher rates of milder symptoms [18].

Comorbidities Associated with Covid

Patients with Subarachnoid hemorrhage plus SARS-COV2 had a greater chance of mortality than patients with subarachnoid hemorrhage without SARS-COV2 or patients with SARS-COV2 without subarachnoid hemorrhage. These individuals had a higher incidence of systemic comorbidities which served as a factor in the elevated risk. Patients with COVID-19 and subarachnoid hemorrhage had higher rates of pneumonia, pulmonary embolism, urinary tract infection, acute kidney damage, liver failure, Heart failure, acute MI, septic shock, and respiratory failure [9]. A study evaluating Patients hospitalized with COVID-19 disease reports a significant and high risk of thrombotic events including stroke and SAH. 52% of Covid -19 patients present SAH, while 95% of them have a history of hypertension and 60% have a history of diabetes Mellitus, 40% have cardio embolism and 5% have vessel disease, and 35% cryptogenic [19]. Hypertension (HTN) and chronic heart disease were the two most common vascular comorbidities, as documented in various studies on ICH in COVID-19 patients [13]. Due to the resulting autonomic imbalance, more individuals are developing cardiac arrhythmias as the coronavirus 2019 pandemic advances relentlessly. The most frequent rhythm disturbance in COVID-19 infection patients is sinus tachycardia, which can be brought on by fever, hypoxia, and hemodynamic compromise. Transient sinus bradycardia is also a potential sign of COVID-19, according to a retrospective series of 4 patients. Numerous ventricular arrhythmias can happen as a result of triggers such as COVID-19 infection-induced systemic inflammation and severe respiratory insufficiency. Additionally, many medications used to treat COVID-19 infection have the potential to affect the cardiac system by lengthening the QT interval and inducing polymorphic Ventricular Tachycardia (VT) in the form of Torsade de pointes (TdP) [20].

A hemorrhage was found in a group of covid 19 patients 67 years old where the majority of comorbidities diseases were hypertension, diabetes, and obesity. SARS-CoV-2 may raise blood pressure and increase the risk of cerebral hemorrhage once it enters the bloodstream, especially in people who already have high blood pressure [21]. When compared to controls, patients with spontaneous ICH or SAH and concurrent COVID infection were more likely to be members of racial or ethnic minorities, diabetics, and obese, and they also had higher mortality rates and longer hospital lengths of stay [22]. Diabetic patients were more likely to be admitted to the intensive care unit (ICU) during the SARS epidemic at a rate that was higher than that of non-diabetic patients. Research and Reviews proved that diabetic patients have a significantly lower absolute lymphocyte count than those who do not have diabetes. Clinical studies revealed that once diabetic individuals contracted SARS-CoV2 due to a variety of causes such as decreased physical activity and irregular nutrition, the insulin dose rose and blood glucose control became challenging. Additionally, as the virus employs the human angiotensin-converting enzyme (ACE2) as a receptor for cellular entrance, which enhances personto- person transmission, the increased infectivity and virulence of SARS-CoV2 in diabetes is explained. Noting that the reninangiotensin system (RAS) family, which has been linked to diabetes, contains the key component ACE2 [23].

Additionally, a review of the international Health Outcome Predictive Evaluation for SARS-COV2 registry evaluating the effect of renal function on admission and mortality with SARS-CoV-2 infection found that 30% of patients had kidney dysfunction upon admission and that CKD was prevalent in 8.5 % of infected patients [24]. In COVID-19, AKI is linked to a greater risk of death. A case in point is sepsis. Microvascular dysfunction, a rise in vascular permeability, and tissue damage are its defining characteristics. Cardiomyopathy, viral myocarditis, and left ventricular failure are additional conditions that can cause hemodynamic abnormalities. Additionally, cytotoxic reactions harm podocytes and tubules and cause hematuria, proteinuria, and AKI. Moreover, collapsing glomerulopathy is an extra consequence that is brought on by a direct viral effect, the presence of increased cytokines from the systemic inflammatory response, or both [25].

Risk Factors for Covid and SAH

Risk factors of high-rate mortality are based on a cohort study, Elevated INR, severe pulmonary symptoms, and spontaneous hemorrhagic presentation [26]. Cigarette smoking, cocaine use, hypertension, low body mass index, first-degree relatives with hemorrhagic stroke, caffeine in pharmaceutical products, lower educational attainment, and nicotine in pharmaceutical products are all risk factors for SAH that can be modified. Age, sex, and race are further risk variables that cannot be changed [27]. To be more specific hypertension can classify as the first and the most notable risk factor caused by SAH in human beings regardless of age and sex which’s followed by the second risk factor in young males is cigarette smoking and hypercholesterolemia in the older woman [10]. There is a strong association between a higher risk of Intracranial Aneurysm (IA) and aneurysmal Subarachnoid Hemorrhage (aSAH) and genetic propensity to smoking, sleeplessness, and high blood pressure. The risk of IA and aSAH may also be influenced by factors like physical activity, body mass index, triglyceride levels, and lowdensity lipoprotein cholesterol levels. These findings support the triangulation of information regarding IA and aSAH risk factors and call for additional research in future extensive MR and other epidemiological studies. The biggest risk factors for IA and aSAH, according to the current MR study, include smoking and high blood pressure. Additionally, this study discovered data that suggests insomnia may be a brand-new risk factor for IA and aSAH [28].

In the indirect way of SAH hemodynamic stress, chronic inflammation and vascular wall remodeling are the most common causes of the ruptured Cerebral aneurysm which leads by the reactive oxygen species through the activation of nuclear factor Kappa-B to the endothelial dysfunction. Hemodynamic stress is brought on by the activation of the renin-angiotensin system, which causes hypertension. Unlimited consumption of (alcohol, antioxidants vitamins, B vitamins, flavonoids, and n-3 fatty acids) leads to increased blood pressure which increases the risk of the rupture of cerebral aneurysm and causes SAH [29]. The most important risk factors of SAH based on studies are Smoking, hypertension, and excessive alcohol consumption, Besides, there are many other uncertain factors such as nonwhite ethnicity, HRT, hypercholesterolemia, and diabetes in the etiology [30,31]. Cigarette smoking and hypertension increase the risk of cerebrovascular diseases which are the main causes of SAH. However, cigarette smoking cessation doesn’t decrease this risk [32].

Regarding covid 19, The Elderly COVID-19 patients, who had a higher risk of hospitalization, mechanical ventilation, and mortality, demonstrated dyspnea as a risk factor. Additionally, because of weakened immunity, patients with cancer and hematologic malignancies are more susceptible to SARS-CoV-2 infection. An Individual may be more susceptible to COVID-19 infection if they are pregnant in addition to these risk factors. This may be due to physiological changes in the immune system and placental immaturity during the first trimester [33]. One of the most important complications of Covid 19 disease is thrombosis, while preventing this thrombotic complication by using antithrombotic agents, there are important side effects, from the use of these agents, such as hemorrhagic stroke, subarachnoid hemorrhage, and intracranial bleeding [34].

Complications

Major Complication Associated with SARS-CoV-19

Pneumonia: The Lower respiratory tract’s innate and acquired defense systems produce an inflammatory response after infection, as in the case of SARS-CoV-19. The cytokines TNF-a, IL-8, and IL-1 released by the resident alveolar macrophage in the lungs attract inflammatory cells like neutrophils to the parenchyma thereby generating clinically symptomatic pneumonia [35,36]. Additionally, the macrophages function as Antigen-presenting T-cells (APC)s, activating a plethora of immune responses, cell-mediated, humoral, complement-activated, and antibody-production. As a result, the lung parenchyma becomes inflamed, and capillary leakage leads to fluid-filled alveolar sacs, thus producing the fundamental pathogenesis of pneumonia [36]. Patients experience productive cough (greenish, yellow, or bloody mucus), tachycardia, tachypnea, fever with chills, malaise, loss of appetite, and myalgia. A fraction experience altered mental status, abdominal pain, stabbing chest pain and further systemic findings. Physical examination common findings include crackles, dullness on percussion and egophony and tactile fremitus (both suggestive of consolidation) [35,36].

Acute Respiratory Distress Syndrome (ARDS)

ARDS is a cause of respiratory failure in critically ill patients and is the acute onset of pulmonary edema (noncardiogenic), atelectasis, hypoxemia and the need of mechanical ventilation. ARDS is marked by increased permeability to fluid and protein across the lung endothelium leading to edema in the lung interstitium. Damaged tight junctions between type I and II alveoli, the edematous fluid translocate into the alveoli space. Typical hallmarks of ARDS include increased permeability to fluid, proteins, neutrophils and RBCs, leading to their accumulation within alveolar space [37]. Vascular hypoxemia seen is caused by ventilation-to-perfusion disbalance as well as right-to-left intrapulmonary shunting. Furthermore, hindered carbon dioxide excretion is a major component of respiratory failure, resulting in increased pulmonary dead space with elevated ventilation [37]. Increasing pulmonary dead space and decreasing respiratory compliance are predictors of ARDS mortality [37]. Diffuse alveolar damage (DAD) is the main pathologic finding and is characterized by the destruction of both alveolar type I and II cells. This ultimately leads to pulmonary edema as the destroyed alveolar type II cannot remove leaked fluid, this then is followed by hyaline membrane depository on the alveolar walls. During this time, surfactant produced by alveolar type II cells cannot reduce surface tension and inflate the alveoli for respiration. During the recovery process, collagen deposited may not be completely reabsorbed, limiting alveolar expansion and thus respiration [37,38]. A plethora of problems arises from ARDS which can be seen in the Table 1 below [37,38].

biomedres-openaccess-journal-bjstr

Table 1: Further systemic complications of ARDS. It can be seen that ARDS in its own right is a complication, yet it can bring additional problems that can ultimately lead to death.

Multi-Organ Failure and Death

Whilst common cold symptoms are observed in mild forms of COVID-19. In severe cases, there is the involvement of different organs that can quite frequently lead to death, often characterized by acute lung failure, liver failure, kidney injury and cardiovascular disease, and a spectrum of hematological and neurological abnormalities [39,40]. It is suggested that the main cause of multi-organ failure is the cytokine storm, which is induced by inflammatory mediators, endothelial dysfunction, coagulation abnormalities, and inflammatory cell organ infiltration [40]. Along with the plethora of complications previously mentioned, death can ultimately occur and can be a result of multi-organ failure or any other complication such as ARDS or Acute heart failure [39,40].

Common Complications Pertaining SAH and SARS-CoV-19.

In comparison to COVID-19, some patients with the condition: SAH (Subarachnoid Hemorrhage) will survive and make a satisfactory recovery. However, a significant number of individuals still do develop serious complications which further decline their health and can potentially lead to death. Complications can be classified into intracranial or extracranial where, according to Hall and O’Kane (2018), intracranial consequences are factored in the initial treatment while the latter is closely monitored [41]. Furthermore, according to Daniere et al., complications can also vary in severity, from acute, subacute, and chronic listing the following in respective order: hydrocephalus, vasospasms, and cognitive disorders [42]. In many instances, the complications can be closely related to the activation of the sympathetic nervous system, catecholamines, and the systemic inflammatory response syndrome (SIRs) (Garg and Bar, 2017) [43]. Data supported by Hammer et al., (2020), has shown that the following are statistically significant complications found after SAH: pneumonia, sepsis, hydrocephalus, and delayed cerebral ischemia [44]. Apart from the neurological complications seen in SAH, a patient may also develop secondary non-neurological conditions, such as neurocardiogenic injury, pulmonary edema, and hyperglycemia (Chen, et al. [45]). From these non-neurological conditions, it is common to observe cardiac and pulmonary manifestations following the complication of SAH [38].

Conclusion

This case study and literature analysis on COVID-19 and SAH established that patients with a prior COVID-19 infection have a higher likelihood of developing SAH as opposed to patients who have not acquired COVID-19. The primary etiology of SAH during COVID-19 infection was proven to be thrombotic vascular events, which caused microvascular lesions of cerebral hemorrhage and disrupted the angioarchitecture. Additionally, these lesions were most frequently seen in patients with a history of comorbidities like diabetes mellitus and hypertension resulting in higher mortality rates. Regardless of the patient’s age or comorbidities, the ratio of major respiratory complications such as pneumonia and ARDS were significantly higher. The major determinants of higher mortality in patients with SAH and COVID-19 were elevated INR, insidious pulmonary presentations (effusion, ARDS, pneumonia), and spontaneous hemorrhagic conditions. It was further noted that the strokes were typically initiated after the COVID-19- associated lung infection had completely subsided in the body. Furthermore, this led to coagulation in the arteriovenous system of the brain, resulting in the individual becoming more prone to brain hemorrhages. Although there were generalized reviews stating that COVID-19 infection caused an increase in the intracranial pressure while simultaneously surging the risk of aneurysms, there was ambiguity in the data that determined the underlying mechanism of the aforementioned. Consequently, thorough research in this area would be beneficial in determining factual data.


Follow us for more Articles on: https://biomedres01.blogspot.com/

https://scholar.google.com/citations?user=OFtUOZYAAAAJ&hl=en
https://www.base-search.net/Search/Results?lookfor=Biomed+Journal+of+Scientific+%26+Technical+Research&l=en&refid=dcsuggesten
https://citefactor.org/journal/2574-1241/biomedical-journal-of-scientific-technical-research
https://ideas.repec.org/s/abf/journl.html
https://econpapers.repec.org/article/abfjournl/
https://www.ncbi.nlm.nih.gov/nlmcatalog/101723284
https://bjstr.org/
https://bjstr.org/about.php
https://biomedres.us/reprints.php
https://biomedres.net/submit-manuscript.php
https://independent.academia.edu/BJSTRAngelaRoy

Light Therapy in Parkinson’s Disease

 

Light Therapy in Parkinson’s Disease

Introduction

Parkinson’s disease is a movement disorder resulting from the loss of dopaminergic neurons of the midbrain. This causes resting tremor, akinesia and rigidity often associated with cognitive decline and early death. The current medical treatment with L-Dopa is very effective in attenuating the motor signs, at least initially but eventually neurosurgery can be needed with implantation of electrodes and deep brain stimulation. These treatments however do not reliably alter the slow progression of the disease and neurons continue to die. Despite an intense search for the specific cause of this neurodegenerative disease there is also a need to look towards developing an approach that will regulate the self repair mechanisms of neurons. This will potentially alleviate, or at least slow, the progression of Parkinson’s and perhaps other neurodegenerative disease. Red to infrared light therapy (600-1070 wavelength) is emerging as an effective, repair orientated therapy that may be capable of regulating specific neuronal functions, as well as being neuroprotective and stabilising dying neurons (Johnstone, et al. [1]). In Parkinson’s disease light therapy can be applied directly or indirectly to the substantia nigra pars compacta (SNc) of the midbrain. More recently there have been anecdotal reports of the benefits of light therapy by its affect on the gut microbiome (“photobiomodulation”) via the vagus nerve (Liebert, 2019).

Parkinson’s Disease

Parkinson’s disease is a slow, progressive neurodegenerative disease of insidious onset causing resting tremor, rigidity, akinesia and bradykinesia (Jancovic, et al. [2]). This is due to loss of pigmented dopaminergic neurons in the SNc and other nuclei of the basal ganglia causing abnormal neuronal activity (Blandini, et al. [3]). In a small number of cases defective genes contribute to the development of Parkinson’s disease.It may also be caused by exposure to a neurotoxin occurring many years prior to the onset of clinical signs (Bove, et al. [4]). Mitochondrial dysfunction however plays the central role underpinning the degeneration of dopaminergic neurons, whether by toxic insult or genetic defect, with progressive accumulation of mutations in mitochondrial DNA (Exner, et al. [5]). Neurodegeneration leads to the accumulation of abnormal proteins (Lewy bodies) within the neurons (Goedert, et al. [6]) together with glutamate excitotoxicity and local inflammation in the SNc (Whitton, et al. [7]).

Management of Parkinson’s Disease

Current treatment for most patients is replacement dopamine drug therapy. In some patients surgery is needed to correct the abnormal function of the basal ganglia circuitry caused by the loss of dopamine. This occurs when medication becomes ineffective or with progressive disease where further symptomatic relief is needed. Three types of drug therapy are used to enhance the defective dopamine pathway (Shapira, et al. [8]). First line treatment is usually L-Dopa (levodopa), a precursor to dopamine, which quickly reduces the motor signs but its efficacy reduces over time. Within several years involuntary movements (dyskinesia) appear, especially in the upper limbs, due to dysregulation of the dopaminergic receptors. Second line drug therapy uses dopamine agonists which mimic the action of dopamine and activate the dopamine receptors of neurons directly. These have fewer motor complications and are often the treatment choice in younger patients.

The final group of drugs are monoamine oxidase inhibitors which help to stop the breakdown of dopamine at the synapse, thereby increasing availability to the postsynaptic neurons (Worth, 2013). Drug treatments give early good symptomatic relief but there is little evidence they are neuroprotective, and they do not slow the pathology of the disease or stop neuronal death (Hart, et al. [9]). Surgical treatment is reserved after drug treatments fail to relieve symptoms and dyskinesia develops. The basic surgical principle is to target and correct the abnormal motor activity of basal ganglia nuclei and thalamus due to reduction of dopamine levels. The nuclei targeted are usually the motor nuclei of the thalamus, the globus pallidus and the subthalamic nucleus with the aim of reducing tremor, akinesia and rigidity.Initial surgical efforts were directed at destructive lesions but more recently deep brain stimulation using implanted electrodes at high frequency is used to dampen the abnormal activity in these nuclei (Ashkan, et al. [10]). This has low morbidity with effective long term management of motor signs but little evidence of slowing of the pathological process (Charles, et al. [11]) and prevention of neuronal death (Wallace, et al. [12]).

Neuroprotection Using Light Therapy

There is both basic science and clinical evidence for neuroprotection in Parkinson’s disease by light therapy using low level laser red to infrared light of 600-1,070nm. The process may have evolved in epithelial tissues and remain inducible in the neuroepithelium. This common mechanism is suggested by light therapy success in many different models of disease in a range of neural systems such as depression (Schiffer, et al. [13]) and age related macular degeneration (Rojas, et al. [14]). The mechanisms involved are not entirely clear but the most compelling evidence suggests direct stimulation of the mitochondria boosting their function via an increase in ATP production (Rojas, et al. [14]). This primary mechanism is supported by the indirect stimulation of the immune system and stem cells (Byrnes, 2005). These stimulated cells may release trophic factors such as nerve growth factor and vascular endothelial growth factor that improve the function of dying cells with a reduction in apoptosis (Hou, et al. [15]). There have been promising experimental results in animal models indicating that light therapy both protects healthy neurons and also rescues damaged neurons by increasing ATP levels (Peoples, et al. [16]). Neuroprotection studies show far better outcomes when therapy is started earlier in the disease process with less prior neuronal degeneration (Ashkan, et al. [17]). Light therapy also appears to restore function to salvaged neurons (Shaw, et al. [18]) but it is not clear how much light is required and how it should be administered to achieve neuronal survival (Rojas, 2017). Light applied in bursts may be more effective in short pulses rather than being applied continuously (Oron, et al. [19]).

Human Studies

Despite promising experimental results in animal models there have been no major clinical trials of light therapy in patients with Parkinson’s disease, only anecdotal reports and non randomised studies (Maloney, et al. [20]). An obvious problem is delivery of light applied from an external source to deeper brain structures in humans. Attempts are currently underway to develop an intracranial light optical fibre device to deliver a strong light signal deep into the brain near the SNc (Johnstone, et al. [21]). Clearly there are many advantages in using light therapy for Parkinson’s disease, especially its potential to be neuroprotective. Also, it appears to be free of any side effects with a large safety margin (Mc Carthy, et al. [22]). Treatment with light therapy is also relatively uncomplicated. The patient would require a minimally invasive surgical stereotactic procedure for the insertion of a light optical device into the brain linked to a pacemaker and battery. (McGeer PL, et al. [23]). The light is applied to the SNc as required, similar to single electrode deep brain stimulation currently being used with comparable procedural risks (Benabid, et al. [24]).

The Gut Microbiome and Parkinson’s Disease

There is a particularly strong link between the microbiome and Parkinson’s disease. Constipation affects over 90 per cent of patients with Parkinson’s disease often preceding the diagnosis by many years (Perez-Pardoa, et al. [25]). The disease is also more common in those who have irritable bowel disease (Jankovic, et al. [26]) and the gut microbiome in Parkinson’s patients has been shown to be altered compared to the general population (Parashar, et al. [27]). The current hypothesis suggests that local inflammation in the gut excites an inflammatory response with increased production and excess accumulation of a protein, alpha synuclein. Some of this excess may be transported to the brain via the vagus nerve (Bravo, et al. [28]). Abnormal accumulation of this protein in nerve cells produce Lewy bodies which are present in high numbers in the brain of patients with Parkinson’s disease and have been detected in the gastrointestinal tract of these patients many years prior to their diagnosis (Derkinderen, et al. [29])

The vagus nerve begins from a number of nuclei in the lower brain stem and supplies the gastrointestinal tract down to the first half of the large intestine. Patients who have undergone surgical transaction of the vagus are known to be less likely to develop Parkinson’s disease (Klingelhoefer, et al. [30]). Direct communication between the microbiome and the brain is theoretically possible through the vagus nerve which provides a direct link to the enteric, or autonomic, nervous system (Pavlov, et al. [31]). The latter communicates directly with the gut lumen and is exposed to microbially produced neurotransmitters (Bravo, et al. [28]). Endocrine cells in the gastrointestinal tract have been shown to synapse with the vagus nerve and transmit signals directly from the gut to the brain in a single synapse (Kaelberer, et al. [32]). The vagus nerve can influence gut motility and mucin secretion both of which will affect the microbiome (Mayer, et al. [33]). As well short chain fatty acids produced by the microbiome can directly influence the sympathetic nervous system (Kimura, et al. [34]).

Improvement in the gut microbiome may reduce gastrointestinal tract inflammation and permeability which should reduce alpha synuclein production and transportation to the brain (Sherwin, et al. [35,36]). Theoretically the risk of Parkinson’s disease is also reduced by the anticipated increase in beneficial microbial metabolic by-products including serotonin, gamma amino butyric acid and dopamine (Sun, et al. [37]), and symptoms should improve in those who already have the disease. A recent study (Bicknell, et al. [38]) has shown that infrared light delivered as low level laser to the abdomen of healthy mice can produce a significant change in the gut microbiome. It is uncertain whether the light is primarily absorbed by the microbial cells themselves or by the host cells surrounding the microbes or a combination of both. (Willis GL, et al. [39]). The alteration in the microbiome may also be a secondary effect of light affecting the mouse inflammatory response (Hamblin, et al. [40]). A series of experiments on Parkinson’s disease in a mouse model has shown neuroprotection can also be achieved by infrared light delivered to areas of the body remote from the brain (Sampson, et al. [41]). This is postulated to be due to activation of stem and immune cells or a mediator linked to changes in the microbiome (Kim, et al. [42]).

There have been anecdotal reports of improvements in the symptoms of Parkinson’s disease patients including gait disturbance, balance, cognition issues and fine motor skills after receiving infra red light therapy to the abdomen (Bicknell, et al. [2]). These patients showed changes in their gut microbiome with a decrease in some genera of microorganisms that are increased in Parkinsonian patients, and an increase in others that are deficient in these patients (Parashar, et al. [27]) & Liebert, et al. [49]). One of these deficient bacteria (prevotella) is so strongly associated with a more severe form of Parkinson’s disease that it has been proposed as a biomarker for the disease Liebert, et al. [49]). (Imhann F, et al. [43]). The bacteroids in the gut that increased with light therapy are considered beneficial to the microbiome through their antiinflammatory properties and production of healthy short chain fatty acids (Inhann, et al. [43]). Light therapy potentially could act as an adjunct to traditional treatments to rebalance the microbiome, especially dopamine and neurotransmitter production, (Johnstone, et al. [44]) and positively affect the outcome of some difficult to treat patients with Parkinson’s disease (Jenkins, et al. [45-48]).

Conclusion

The discussion of the possible mechanism of action of the effect of light therapy on the human brain either directly or via the microbiome is highly speculative and in its infancy. Early experimental results in animal models however have shown promise that light therapy both protects healthy neurons as well as rescuing damaged dopaminergic neurons. Anecdotal human studies suggest a beneficial neuroprotective outcome of photobiomodulation in patients with neurodegenerative disease. Obviously further research is needed but it is also clear that red to infra red light therapy has the potential to develop into a viable treatment option, or at least an adjunct, for patients with Parkinson’s disease. It offers the potential of neuroprotection and prevention of disease progression to cognitive decline and early death.


Follow us for more Articles on: https://biomedres01.blogspot.com/

https://scholar.google.com/citations?user=OFtUOZYAAAAJ&hl=en
https://www.base-search.net/Search/Results?lookfor=Biomed+Journal+of+Scientific+%26+Technical+Research&l=en&refid=dcsuggesten
https://citefactor.org/journal/2574-1241/biomedical-journal-of-scientific-technical-research
https://ideas.repec.org/s/abf/journl.html
https://econpapers.repec.org/article/abfjournl/
https://www.ncbi.nlm.nih.gov/nlmcatalog/101723284
https://bjstr.org/
https://bjstr.org/about.php
https://biomedres.us/reprints.php
https://biomedres.net/submit-manuscript.php
https://independent.academia.edu/BJSTRAngelaRoy

Tuesday, July 21, 2026

Atypical Appearance of Cameron Lesion Casting Diagnostic Doubt

 

Atypical Appearance of Cameron Lesion Casting Diagnostic Doubt

Introduction

Hiatal hernia (HH) is a common endoscopic finding noted in up to 50% of upper endoscopies performed for another indication [1]. Clinically, HH are predominantly asymptomatic, but can be associated with several complications including gastroesophageal reflux disease [2], iron deficiency anemia [3], acute or chronic bleeding [4], and presence of linear erosion/s or ulcer/s [1]. The latter are found on the crests of gastric mucosal folds at the diaphragmatic impression, and are termed under one name as Cameron lesion/s [1]. Typically, they appear as multiple linear lesions which are frequently associated with chronic occult blood loss and chronic anemia but sometimes, can be the source of life-threatening gastrointestinal (GI) hemorrhage [5,6]. Chronic mechanical trauma and ischemia exerted on the gastric mucosal folds as they move against the diaphragm can be complicated by penetrant ulcer formation. Diagnosis may be challenging as they can be overlooked during endoscopy due to the technical difficulty of endoscopic visualization [7]. Here, we present a case with acute upper GI hemorrhage due to deep penetrant and necrotic ulcerated Cameron lesion which was readily located but misinterpreted as neoplastic lesion based on the endoscopic appearance.

Case Report

A 58-years old man was referred to our Clinic due to the presence of black tarry stools in the last 3 days, accompanied by weakness and malaise. He also noted that in the previous month had been experiencing dyspeptic complaints. The past clinical history was significant for successful eradication therapy for Helicobacter pylori infection 4 years ago, soon after followed by upper GI endoscopic evaluation for prolonged dyspepsia showing sliding hiatal hernia with moderate gastroesophageal reflux erosions. Three years ago, right nephrectomy was performed for renal carcinoma while more than 10 years ago he underwent cholecystectomy due to gallbladder stones. He was on regular antihypertensive therapy, denying use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and had stopped using proton pump inhibitor (PPI) for the gastroesophageal reflux 1 year ago. Biochemical analysis upon admission revealed a reduction in hemoglobin (112 g/L) and mild rise in blood urea nitrogen (9.5 mmol/L). Rectal examination showed traces with dark green and black discoloration. Upon clinical assessment the patient appeared hemodynamically stable with blood pressure of 135/95 mmHg, oxygen saturation of 95% and heart rate of 86 bpm. At urgent upper GI endoscopy, a sliding hiatal hernia with mild gastroesophageal reflux erosions was found, and at endoscope inversion in the stomach a large prominent subcardial gastric fold which extended in the fundus was detected, with a centrally positioned 1 cm in size, deep penetrant ulcer with dark necrotic base. The corpus, antrum and duodenum were normal, and no signs of active or recent bleeding were noted. The patient was placed on nil per mouth and therapy with parenteral hydration and high dose PPI was started. Due to the atypical location of the ulcer with its endoscopic appearance and the clinical presentation of the patient, a control gastroscopy was performed on the 2nd day. The subcardial gastric fold appeared very prominent and bulging with centrally located deep ulcerated lesion, this time with white fibrin base.

Based on this appearance a suspicion for ulcerated neoplastic lesion and possibly gastric submucosal tumor was made, so consequently biopsies from the margins of the ulcer were taken. Histopathological assessment confirmed the absence of neoplastic alterations. As endoscopic ultrasound is not routinely available at our clinic and expertise is lacking, contrast computed tomography (CT) of the abdomen was performed. Findings (Figure 1) were consistent with thickening of the gastric fundic folds with welldefined zone of hypoattenuating oedematous submucosa, and absence of lymph node enlargement. Thus, upon CT evaluation there were no convincing signs of submucosal necrotic lesion. After one week at another control gastroscopy the gastric ulceration was still present (Figure 2), though reduced in depth, with converging thickened prominent gastric folds, so that multiple biopsies were repeated on the lesion. Histological lesions of fibrosis, chronic inflammation and intestinal metaplasia were identified with absence of neoplastic cells. After 1 month on high dose PPI therapy a further endoscopy (Figure 3) was performed showing regression of the ulcer with stellar cicatrix, normal appearing mucosa and voluminous edematous gastric folds. The evolution of the endoscopic and histological changes, location of the ulcer and the presence of HH led us to conclude that this is a Cameron lesion. The patient was continued on long-term high dose PPI therapy and after radiological assessment of the HH was referred for surgical management given the clinically symptomatic HH and initial depth of the ulcer with possible future complications. Upon laparoscopic surgery a large hiatal hernia was identified and further surgical exploration didn’t identify signs of neoplastic intramural lesions. The hiatal opening was about 5 cm wide with herniation of the uper part of stomach. The hernia sac was completely dissected and excised with crural exposure after wich cruroplasty was performed with non-absorbable interrupted sutures. In order to have better reflux control a Dor fundoplication was performed (Figure 4). The patient had uneventful recovery.

biomedres-openaccess-journal-bjstr

Figure 1: Contrast CT of the abdomen demonstrating thickened gastric folds in the fundus of the stomach, adjacent to the diaphragm due to well defined hypoattenuating oedematous submucosa (*) and discrete enhancement of hyperaemic mucosa (thin arrows).

biomedres-openaccess-journal-bjstr

Figure 2: Ulcer presentation at control gastroscopy after one week of initial presentation.

biomedres-openaccess-journal-bjstr

Figure 3: a and b: Control gastroscopy after 1 month. Complete resolution of the ulcer with presence of stellar cicatrix (black arrow) on edematous and voluminous gastric folds near the level of the diaphragm impression (white line) at the neck of the hiatal hernia.

biomedres-openaccess-journal-bjstr

Figure 4:

a. Wide hiatal opening (white arrow) with hiatal hernia.

b. Crural exposure with complete dissection and excision of the hiatal sac.

c. Cruroplasty with non-absorbable interrupted sutures.

d. Dor funduplication for better reflux control.

Discussion

Cameron lesions were first described by Cameron and Higgins in 1986 [6]. Their prospective study including 109 patients with endoscopically proven HH revealed the association of anemia with HH. Anemia was present in 50.5% of the patients (group 1), while 49.5% were not anemic (group 2). In 41.8% of patients in group 1 they identified presence of linear gastric erosions on mucosal folds near the diaphragmatic level which were termed Cameron lesions, and the same were identified in 24% of patients in group 2. Despite being long-known entity, they remain underdiagnosed and underappreciated source mostly for chronic occult blood loss resulting in repetitive GI endoscopic evaluation [7,8]. The prevalence as to be expected is dependent on the size of the HH, reaching to 13% in large hernias (>5cm) [9]. The proposed primary causes of their development are the mechanical trauma and local ischemia exerted on the gastric mucosal folds as they move against the diaphragm [5,10]. They are considered as non-peptic gastric lesions which is supported by the lack of significant positive association with NSAIDs and aspirin use or Helicobacter infection, although mucosal peptic injury can contribute to their formation [1,5,11]. In support of this is that a relatively good proportion of patients have a good outcome with acid suppression therapy [12]. Gastrointestinal bleeding is the consequence of HH associated with Cameron lesion. Most often it is chronic and occult, with irondeficiency anemia, while acute, life-threatening GI hemorrhage is less frequent [8]. They are diagnosed at endoscopy, but their visualization in the hernial sac can be challenging, so a thorough antegrade and retrograde endoscopic assessment is crucial [6,8]. Detection of shallow lesions can be further improved with the use of narrow band imaging (NBI) or magnification chromoendoscopy [13]. At endoscopy, Cameron lesions usually present as single or multiple linear erosions resembling aftoid lesions [6], though deep, fibrotic or necrotic ulcers, as presented in our case, can also develop [14,15]. Additional accompanying findings such as edematous and erythematous surrounding gastric mucosal folds, ecchymotic bleeding can be noted [6].

Erosions and ulcers are termed under one name as Cameron lesion/s to avoid the difficulty of differentiating between erosion or ulcer during endoscopy [1]. Deep lesions can potentially present with visible vessel, and this has been described in one case report where band ligation of the ulcer resulted in successful treatment of life-threatening GI bleeding [16]. In our patient, despite the presence of HH, the depth of the lesion and necrotic base, the atypical localization for an ulcer as well as the pronounced edema of the surrounding gastric folds entangled the diagnosis. Although the CT excluded presence of submucosal lesion we decided to perform additional follow-up endoscopic evaluation for assessment of the healing of the lesion. It was after repeated histological evaluation and demonstration of regression under PPI the lesion was diagnosed as Cameron lesion. Data from the literature shows that therapy of Cameron lesions is mainly PPI [15]. However, use of standard PPI therapy is noted in significant proportion of patients diagnosed with Cameron lesions [8], therefore long-term high dose PPI therapy is necessary. Endoscopic hemostasis is rarely reported and most patients are treated conservatively [15]. In case of actively bleeding lesion endoscopic treatment can be difficult due to anatomical and technical reasons [16] necessitating urgent surgery. For patients who fail medical management surgical HH repair is an option. The distinct pathophysiology of Cameron lesions makes them unique entity and many experts have suggested that relieving the mechanical stress at the neck of the hernia is more adequate for long term resolution. (Verhoeff, et al. [17]) compared surgical and medical treatment of Cameron lesions in their systematic review and meta-analysis. Surgery was superior with 92% therapeutic success compared to 67% for medically managed patients. As demonstrated in our case presentation, presence of dyspeptic complaints associated with HH and occurrence of deep penetrant Cameron lesion were the deciding factors for referral to surgeon. Moreover, slow healing of the lesion was detected while on highdose PPI therapy. This led us to conclude that surgical repair would be of greater benefit both for resolving current Cameron lesion and for preventing future complications, primarily life-threatening GI bleeding and perforation.

Conclusion

Cameron lesions are long-known well described clinical entity, but still remain challenging diagnosis that can be overlooked or misinterpreted. Endoscopists and gastroenterologists should be well aware of this disorder when evaluating a patient with HH, especially in the context of chronic anemia, and detailed evaluation of the hiatal sac should be performed to avoid future unnecessary endoscopic evaluations. Chronic mechanical and ischemic trauma of the gastric folds in the neck of large HH can result in deep ulcer formation presenting with acute, sometimes, life-threatening GI hemorrhage. Misperception of deep, fibrotic and necrotic lesions as neoplastic lesions can result in extensive diagnostic work-up. Medical therapy has a good success, but patients with Cameron lesions associated with large HH (> 5 cm) and those who failed medical therapy should be offered surgery.


Follow us for more Articles on: https://biomedres01.blogspot.com/

https://scholar.google.com/citations?user=OFtUOZYAAAAJ&hl=en
https://www.base-search.net/Search/Results?lookfor=Biomed+Journal+of+Scientific+%26+Technical+Research&l=en&refid=dcsuggesten
https://citefactor.org/journal/2574-1241/biomedical-journal-of-scientific-technical-research
https://ideas.repec.org/s/abf/journl.html
https://econpapers.repec.org/article/abfjournl/
https://www.ncbi.nlm.nih.gov/nlmcatalog/101723284
https://bjstr.org/
https://bjstr.org/about.php
https://biomedres.us/reprints.php
https://biomedres.net/submit-manuscript.php
https://independent.academia.edu/BJSTRAngelaRoy

Bridging the Gap Between COVID-19 and Subarachnoid Hemorrhage: A Case Report and Literature Review

  Bridging the Gap Between COVID-19 and Subarachnoid Hemorrhage: A Case Report and Literature Review Introduction The novel coronavirus was ...